Please login to the form below

Not currently logged in
Email:
Password:

Aveo Oncology

This page shows the latest Aveo Oncology news and features for those working in and with pharma, biotech and healthcare.

AVEO warns EU approval of Fotivda could be at risk

AVEO warns EU approval of Fotivda could be at risk

Concerns arose with overall survival data. AVEO Oncology has revealed in a regulatory filing that European Medicines Agency (EMA) approval for its Fotivda kidney cancer drug could be at risk of ... AVEO’s European licensee EUSA Pharma has been

Latest news

  • Relay Therapeutics strengthens team Relay Therapeutics strengthens team

    Bergstorm joins the biotech from Mersana Therapeutics, where he led the advancement of two oncology products. ... He has held roles for Keryx Biopharmaceutical, Algeta ASA and AVEO Oncology.

  • NICE backs EUSA's RCC treatment Fotivda NICE backs EUSA's RCC treatment Fotivda

    cases. EUSA licenced Fotivda from Aveo Pharmaceuticals back in 2015, but although it has European approval in advanced renal cell carcinoma it failed to gain approval from the US Food and ... However, Aveo Oncology is looking to re-file Fotivda in the

  • Novartis licenses cancer support drug from Aveo Oncology Novartis licenses cancer support drug from Aveo Oncology

    Novartis is paying up to $326m to license rights to a drug developed by Aveo Oncology designed to treat a debilitating symptom of cancer and other diseases. ... Under the terms of the deal, Aveo stands to receive up to $311m in milestones as well as

  • FDA turns down tivozanib for kidney cancer FDA turns down tivozanib for kidney cancer

    Agency describes data provided by Aveo Oncology and Astellas as "uninterpretable". ... The US FDA has declined to approve Aveo Oncology and Astellas' kidney cancer drug tivozanib, saying the results of a pivotal trial supporting the application were

  • Regulatory struggles force Aveo to cut 140 jobs Regulatory struggles force Aveo to cut 140 jobs

    Expects FDA rejection for tivozanib in kidney cancer. Aveo Oncology has announced it will cut 140 jobs based on expectations the US FDA will turn down its lead drug candidate tivozanib ... bringing to a halt Aveo's plans for the drug in the condition.

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    Collaboration – marketing &distribution. $171. AVEO Oncology/ CANbridge Life Sciences. AV-203; ErbB3 (HER3) inhibitory antibody for oesophageal cancer. ... Harvard University/ Merck &Co. Oncology – transcription regulating enzymes for leukaemia

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Research collaboration. 275. Definiens / AstraZeneca (through MedImmune). Tissue Phenomics Dx oncology biomarkers. ... Acquisition of voucher. 125. AVEO Oncology / Ophthotech Corporation. VEGF tyrosine kinase inhibitor tivozanib.

  • Pharma deals during February 2014 Pharma deals during February 2014

    In another termination of an oncology deal, Astellas exercised its right to terminate its collaboration with Aveo Oncology to develop the tyrosine kinase inhibitor, tivozanib, for “strategic reasons”. ... Innate Pharma will prioritise development of

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics